Clinical Trial Update: Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bendamustine hydrochloride for relapsed and primary refractory Hodgkin lymphoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoma

Drugs mentioned

• Bendamustine HCl (Bendamustine hydrochloride)
• Treanda (Bendamustine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hodgkin's Disease, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-19